EpiDisease S.L. is a spin-off founded in 2014 by researchers from the Centre for Biomedical Network Research (CIBER-ISCIII) and the University of Valencia from Spain to offer society new applications and services based on the use of epigenetics.
We develops and commercialises a pipeline of epigenetic proprietary products for earlier and accurate diagnostic and prognostic of human diseases and epigenetic specialised services.
Our first product is intended for Adolescent Idiopathic Scoliosis (AIS), a three-dimensional spinal deformity that affects 1.3M adolescents in Europe, characterised by pain, aesthetic deformity, immense psychological stress and alterations in pulmonary function and is, therefore, an increasing concern for both patients and their relatives. About 10% of AIS can progress towards severe outcome, which requires costly and risky surgery. To date, it is not possible to predict either spine deformity progression or efficacy of braces, so patients are followed up by multiple X-ray radiographs, an approach that increases the risk of cancer in adulthood. Moreover, despite X-rays having no prognostic capability, a fact that clearly evidences the need for developing new methods to improve AIS management.
EpiDisease has developed ScoliPro®, a panel of microRNAs detected in blood to provide a risk factor which correlates with the severity and risk of disease progression, offering a reliable solution to predict spine deformity progression.